Epigenetic therapy for solid tumors: from bench science to clinical trials.
about
Epigenetic therapy in gastrointestinal cancer: the right combinationSpotlight on decitabine for myelodysplastic syndromes in Chinese patientsDiscovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration AnalysisMicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeuticsAddressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesNew Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.Epigenetics in cancer stem cells.Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer.Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy.Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression.Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors.The Role of DNA Methylation in Cancer.Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
P2860
Q26745709-B30A71DE-B755-46EA-8145-CBB06523D27CQ26778454-B3CBDE51-3D3D-48F2-8039-0DB10854EB8DQ27728041-54A5A0DB-CBA2-43AC-A9CD-A062256FEB29Q28068338-7A1B043B-9EC0-4983-AFC8-38D4A27E8DF1Q28074716-BDA6C580-02E8-410B-9CD3-DCDCE2026055Q36085145-5F6E70EB-203E-481E-AE50-C227B60AB66FQ36853857-2CEAA42A-D559-421F-83D0-2D497E08F668Q37618640-5A08CAC1-0F5D-4639-87A6-EC766745C0DBQ37745480-F8A355F1-6815-4663-B4A7-6BCA1598526FQ40432298-C1E3F979-DA7E-432E-A559-FA556102487AQ40577464-B9B6CFCE-EA66-43AB-ABD8-773D560E463AQ41064275-FEF58300-F0C2-4B8D-9622-9F6676E48CC6Q41516113-2A1F8292-50E9-42F3-B9BB-82AA43453806Q52596812-98A3AF34-473A-4367-8B28-59595F5B08B9Q52966734-AE5915CC-0A5E-4611-84F9-8DAB8814B839Q58130496-20553A1F-9788-4C18-8E12-C0E892BABB38
P2860
Epigenetic therapy for solid tumors: from bench science to clinical trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Epigenetic therapy for solid tumors: from bench science to clinical trials.
@en
type
label
Epigenetic therapy for solid tumors: from bench science to clinical trials.
@en
prefLabel
Epigenetic therapy for solid tumors: from bench science to clinical trials.
@en
P2093
P2860
P356
P1433
P1476
Epigenetic therapy for solid tumors: from bench science to clinical trials.
@en
P2093
Ankita Mishra
Nilofer S Azad
Nita Ahuja
Stephen B Baylin
Xue-Jun Gong
Yen-Yi Juo
P2860
P304
P356
10.2217/EPI.14.73
P577
2015-01-01T00:00:00Z